Literature DB >> 18815295

Evolution of CCR5 use before and during coreceptor switching.

Mia Coetzer1, Rebecca Nedellec, Janelle Salkowitz, Sherry McLaughlin, Yi Liu, Laura Heath, James I Mullins, Donald E Mosier.   

Abstract

The envelope gene (env) of human immunodeficiency virus type 1 (HIV-1) undergoes rapid divergence from the transmitted sequence and increasing diversification during the prolonged course of chronic infection in humans. In about half of infected individuals or more, env evolution leads to expansion of the use of entry coreceptor from CCR5 alone to CCR5 and CXCR4. The stochastic nature of this coreceptor switch is not well explained by host selective forces that should be relatively constant between infected individuals. Moreover, differences in the incidence of coreceptor switching among different HIV-1 subtypes suggest that properties of the evolving virus population drive the switch. We evaluated the functional properties of sequential env clones from a patient with evidence of coreceptor switching at 5.67 years of infection. We found an abrupt decline in the ability of viruses to use CCR5 for entry at this time, manifested by a 1- to 2-log increase in susceptibility to CCR5 inhibitors and a reduced ability to infect cell lines with low CCR5 expression. There was an abnormally rapid 5.4% divergence in env sequences from 4.10 to 5.76 years of infection, with the V3 and V4/V5 regions showing the greatest divergence and evidence of positive selection. These observations suggest that a decline in the fitness of R5 virus populations may be one driving force that permits the emergence of R5X4 variants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18815295      PMCID: PMC2583682          DOI: 10.1128/JVI.01141-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Selection on the human immunodeficiency virus type 1 proteome following primary infection.

Authors:  Yi Liu; John McNevin; Jianhong Cao; Hong Zhao; Indira Genowati; Kim Wong; Sherry McLaughlin; Matthew D McSweyn; Kurt Diem; Claire E Stevens; Janine Maenza; Hongxia He; David C Nickle; Daniel Shriner; Sarah E Holte; Ann C Collier; Lawrence Corey; M Juliana McElrath; James I Mullins
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates.

Authors:  Mia Coetzer; Tonie Cilliers; Li-Hua Ping; Ronald Swanstrom; Lynn Morris
Journal:  Virology       Date:  2006-08-30       Impact factor: 3.616

Review 3.  V3: HIV's switch-hitter.

Authors:  Oliver Hartley; Per Johan Klasse; Quentin J Sattentau; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2005-02       Impact factor: 2.205

4.  Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.

Authors:  Zabrina L Brumme; James Goodrich; Howard B Mayer; Chanson J Brumme; Bethany M Henrick; Brian Wynhoven; Jerome J Asselin; Peter K Cheung; Robert S Hogg; Julio S G Montaner; P Richard Harrigan
Journal:  J Infect Dis       Date:  2005-06-23       Impact factor: 5.226

5.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host.

Authors:  Joshua T Herbeck; David C Nickle; Gerald H Learn; Geoffrey S Gottlieb; Marcel E Curlin; Laura Heath; James I Mullins
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection.

Authors:  Graeme J Moyle; Adrian Wildfire; Sundhiya Mandalia; Howard Mayer; James Goodrich; Jeannette Whitcomb; Brian G Gazzard
Journal:  J Infect Dis       Date:  2005-02-11       Impact factor: 5.226

8.  Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.

Authors:  Mike Westby; Marilyn Lewis; Jeannette Whitcomb; Mike Youle; Anton L Pozniak; Ian T James; Tim M Jenkins; Manos Perros; Elna van der Ryst
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 9.  HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes.

Authors:  Maureen M Goodenow; Ronald G Collman
Journal:  J Leukoc Biol       Date:  2006-08-21       Impact factor: 4.962

10.  Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.

Authors:  Guerau Fernàndez; Anuska Llano; Miriam Esgleas; Bonaventura Clotet; José A Esté; Miguel Angel Martínez
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

View more
  23 in total

1.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

2.  Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.

Authors:  Mia Coetzer; Rebecca Nedellec; Tonie Cilliers; Tammy Meyers; Lynn Morris; Donald E Mosier
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

3.  Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Authors:  Nikolaos Chatziandreou; Ana Belen Arauz; Ines Freitas; Phyu Hninn Nyein; Gregory Fenton; Shruti H Mehta; Gregory D Kirk; Manish Sagar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

Review 4.  Coreceptors and HIV-1 pathogenesis.

Authors:  Paul R Gorry; Petronela Ancuta
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

5.  Co-receptor tropism prediction among 1045 Indian HIV-1 subtype C sequences: Therapeutic implications for India.

Authors:  Ujjwal Neogi; Sreenivasa B Prarthana; George D'Souza; Ayesha Decosta; Vijesh S Kuttiatt; Udaykumar Ranga; Anita Shet
Journal:  AIDS Res Ther       Date:  2010-07-21       Impact factor: 2.250

6.  Development of a novel codon-specific polymerase chain reaction for the detection of CXCR4-utilizing HIV type 1 subtype B.

Authors:  Sherry McLaughlin; Luke C Swenson; Shengbo Hu; Paul Hughes; P Richard Harrigan; Robert W Coombs; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-06       Impact factor: 2.205

7.  Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry.

Authors:  Lamorris M Loftin; Martha F Kienzle; Yanjie Yi; Benhur Lee; Fang-Hua Lee; Lachlan Gray; Paul R Gorry; Ronald G Collman
Journal:  Virology       Date:  2010-04-09       Impact factor: 3.616

8.  High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia.

Authors:  Rebecca Nedellec; Joshua T Herbeck; Peter W Hunt; Steven G Deeks; James I Mullins; Elizabeth D Anton; Jacqueline D Reeves; Donald E Mosier
Journal:  AIDS Res Hum Retroviruses       Date:  2016-10-12       Impact factor: 2.205

9.  Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates.

Authors:  Ashika Singh; Taryn Page; Penny L Moore; Rachel L Allgaier; Keshni Hiramen; Hoosen M Coovadia; Bruce D Walker; Lynn Morris; Thumbi Ndung'u
Journal:  Virology       Date:  2009-08-19       Impact factor: 3.616

10.  Understanding the HIV coreceptor switch from a dynamical perspective.

Authors:  Christel Kamp
Journal:  BMC Evol Biol       Date:  2009-11-30       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.